课题基金 / 基金详情

PHASE I STUDY OF BB 10010 IN PATIENTS WITH RELASPED/REFRACTORY BREAST CANCER

PHASE I STUDY OF BB 10010 IN PATIENTS WITH RELASPED/REFRACTORY BREAST CANCER
BB 10010 在复发/难治性乳腺癌患者中的 I 期研究
批准号：
6290961
负责人：
Michael Gordon
金额：
$1.7万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6290961
关键词：
antineoplastics blood cell count bone marrow breast neoplasms chemokine clinical research clinical trial phase I drug adverse effect drug screening /evaluation human subject immunosuppression neoplasm /cancer chemotherapy

项目摘要

项目成果

Michael Gordon的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Dose-intensive chemotherapy is associated with myelosuppressive complications including neutropenia and theombocytopenia. Currently availabe hamatopoietic growth factors are able to reduce the former complication, but thrombocytopenia, and cumulative myelosuppression remain significant complications of these treatments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE I TRIAL OF MINOCYCLINE IN PATIENTS WITH CANCER
PHASE I STUDY OF BB 10010 IN PATIENTS WITH RELASPED/REFRACTORY BREAST CANCER
STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF
STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF
海外基金